The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own treatment, Eli Lilly said of the results presented at the European Congress on Obesity and published in the New England Journal of Medicine.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what researchers found.